SG11201903521XA - Pharmaceutical formulations and methods of making the same - Google Patents

Pharmaceutical formulations and methods of making the same

Info

Publication number
SG11201903521XA
SG11201903521XA SG11201903521XA SG11201903521XA SG11201903521XA SG 11201903521X A SG11201903521X A SG 11201903521XA SG 11201903521X A SG11201903521X A SG 11201903521XA SG 11201903521X A SG11201903521X A SG 11201903521XA SG 11201903521X A SG11201903521X A SG 11201903521XA
Authority
SG
Singapore
Prior art keywords
sast
international
120naci
100naci
passt
Prior art date
Application number
SG11201903521XA
Inventor
Monica Goss
Nicole Ball
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11201903521XA publication Critical patent/SG11201903521XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE 3E1 0 011101 1111011 Mil OFR 11110 1111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/075818 Al 26 April 2018 (26.04.2018) WIP0 I PCT (51) International Patent A61K 9/08 (2006.01) A61K 31/70 (2006.01) A61K 47/42 (2017.01) (21) International Application (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/411,458 (71) Applicant: AMGEN Drive, Thousand Oaks, California 91320-1799 (US). (72) Inventors: GOSS, bury Park, California _ Heatherglow Street, Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61P 29/00 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, CO7K 1/34 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, C07K 14/705 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US2017/057472 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every 19 October 2017 (19.10.2017) kind of regional protection available): ARIPO (BW, GH, English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 21 October 2016 (21.10.2016) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, INC. [US/US]; One Amgen Center KM, ML, MR, NE, SN, TD, TG). Monica; 3050 Lodgewood Street, New- Declarations under Rule 4.17: 91320 (US). BALL, Nicole; 3260 — as to applicant's entitlement to apply for and be granted a Thousand Oaks, California 91360 patent (Rule 4.1700) Published: Karoline A.; Knobbe, Martens, 01- — with international search report (Art. 21(3)) Main Street, 14th Floor, Irvine, CA — with sequence listing part of description (Rule 5.2(a)) (unless otherwise indicated, for every available): AE, AG, AL, AM, BB, BG, BH, BN, BR, BW, BY, BZ, CR, CU, CZ, DE, DJ, DK, DM, DO, (US). = (74) Agent: DELANEY, = son & Bear, LLP, 2040 92614 (US). = (81) Designated States kind of national protection __ AO, AT, AU, AZ, BA, _ — CA, CH, CL, CN, CO, = = Figure 1: Percent HMW (peak B) as detected by SEC 25 20 15 to 41 O. 10 FORMULATIONS AND METHODS OF MAKING THE SAME Percent Peak B by SEC —i—PASST 4°C also relates to (54) Title: PHARMACEUTICAL = = = = = --M—SAST_100NaCI 4°C • 40°C —A— SAST_120NaCI 4 ° C = co • • 5 : • —41— PASST 25 ° C Z: .:A . — M — SAST_100NaCI 25°C ,, It SAST_120NaCI 25°C • ••• • PASST 40°C :.. • • g• • SAST_100NaCI 40°C • .:: • • •A• • SAST_120NaCI 40 ° C I ,.. .. 25°C d - -a-- 41 - ''' e. - r • 4 ° C • • • = _ = .... _ PSI GC 1-1 pc Ir) IN © ---.... Il © ei (57) : The invention 0 5 methods of removing buffer and of formulating pharmaceutical compositions of etanercept. 0 , 0 10 20 30 40 50 Time (weeks) relates to the formulation of pharmaceutical compositions of etanercept. The invention
SG11201903521XA 2016-10-21 2017-10-19 Pharmaceutical formulations and methods of making the same SG11201903521XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662411458P 2016-10-21 2016-10-21
PCT/US2017/057472 WO2018075818A1 (en) 2016-10-21 2017-10-19 Pharmaceutical formulations and methods of making the same

Publications (1)

Publication Number Publication Date
SG11201903521XA true SG11201903521XA (en) 2019-05-30

Family

ID=61971152

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903521XA SG11201903521XA (en) 2016-10-21 2017-10-19 Pharmaceutical formulations and methods of making the same

Country Status (14)

Country Link
US (4) US20180110856A1 (en)
EP (1) EP3528787A4 (en)
JP (3) JP6884858B2 (en)
KR (2) KR102413592B1 (en)
CN (2) CN109982685B (en)
AU (1) AU2017345490B2 (en)
BR (1) BR112019007858A2 (en)
CA (1) CA3040899A1 (en)
CL (1) CL2019001053A1 (en)
EA (1) EA201990998A1 (en)
IL (1) IL266132B (en)
MX (1) MX2019004580A (en)
SG (1) SG11201903521XA (en)
WO (1) WO2018075818A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006259664A1 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
AU2017345490B2 (en) * 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
US20230146593A1 (en) 2020-03-12 2023-05-11 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
EP4007164A4 (en) 2020-05-12 2022-11-23 NEC Corporation Distortion compensation device and distortion compensation method

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2837168A1 (en) 1978-08-25 1980-03-06 Blutspendedienst Dt Rote Kreuz METHOD FOR PRODUCING AN IMMUNAL GLOBULIN SOLUTION SUITABLE FOR INTRAVENOUS APPLICATION
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4360457A (en) 1979-08-30 1982-11-23 Teijin Limited S-Sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4396608A (en) 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US5702699A (en) 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US4681713A (en) 1984-03-15 1987-07-21 Toyo Boseki Kabushiki Kaisha Method of making a hollow fiber membrane for dialysis
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US6673347B1 (en) 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
GB8628104D0 (en) 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
DE3640513A1 (en) 1986-11-27 1988-06-09 Biotest Pharma Gmbh METHOD FOR THE PRODUCTION OF A VIRUS-SAFE, STORAGE-STABLE AND INTRAVENOES COMPATIBLE IMMUNGLOBULIN-G-PRAEPARATES
JP2547556B2 (en) 1987-02-06 1996-10-23 株式会社 ミドリ十字 Liquid formulation of r-globulin
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (en) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
DE3939346A1 (en) 1989-11-29 1991-06-06 Behringwerke Ag MEDICINES FOR SUBCUTANEOUS OR INTRAMUSCULAR APPLICATION CONTAINING POLYPEPTIDES
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
GB9017002D0 (en) 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
JP3179538B2 (en) 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト Aqueous solution of stable human calcitonin
US5110910A (en) 1991-03-25 1992-05-05 Miles Inc. Virucidal euglobulin precipitation
US5256571A (en) 1991-05-01 1993-10-26 Cytyc Corporation Cell preservative solution
CA2126182C (en) 1991-12-20 2001-07-17 Man S. Co Humanized antibodies reactive with gpiib/iiia
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
DE4344824C1 (en) 1993-12-28 1995-08-31 Immuno Ag Highly concentrated immunoglobulin preparation and process for its preparation
GB9401448D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Stable dry powders
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
DE69534530T2 (en) 1994-08-12 2006-07-06 Immunomedics, Inc. FOR B-CELL LYMPHOMA AND LEUKEMIA SPECIMEN IMMUNOCONJUGATES AND HUMAN ANTIBODIES
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE69721548T2 (en) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMAN ANTIBODIES THAT BIND TO HUMAN TNFalpha
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP2000515857A (en) 1996-07-18 2000-11-28 シーエスエル リミテッド Pasteurization of immunoglobulin solution
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
JP3679406B2 (en) 1998-05-20 2005-08-03 協和醗酵工業株式会社 Recombinant antibody
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US6281336B1 (en) 1998-06-09 2001-08-28 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
US6610206B1 (en) 1998-10-20 2003-08-26 Advanced Renal Technologies Buffered compositions for dialysis
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
CA2362126C (en) 1999-02-03 2017-01-17 Amgen Inc. B7rp-1 polypeptides
US6559122B1 (en) 1999-04-08 2003-05-06 Genentech, Inc. Formulated composition
RU2225221C2 (en) 1999-04-09 2004-03-10 Орто-Макнейл Фармасьютикал, Инк. Pharmaceutical compositions of erythropoietin
WO2000062790A2 (en) 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CA2386228A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) polypeptides
DK1237575T3 (en) 1999-12-14 2008-12-08 Genentech Inc TNF alpha antagonist and LFA-1 antagonist for the treatment of rheumatoid arthritis
AU2262501A (en) 1999-12-16 2001-06-25 Amgen, Inc. Tnfr/opg-like molecules and uses thereof
WO2001058473A1 (en) 2000-02-10 2001-08-16 Wyeth Method of treating or inhibiting cellular injury or cell death
AU2002224555A1 (en) 2000-07-25 2002-02-05 Takeda Chemical Industries Ltd. Process for producing recombinant protein
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
JP5485489B2 (en) 2000-08-11 2014-05-07 中外製薬株式会社 Antibody-containing stabilized preparation
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
NZ526569A (en) 2000-12-14 2005-07-29 Fujisawa Pharmaceutical Co Silenced anti-CD28 antibodies and use thereof for inducing T-cell tolerance, providing immunosupression and treating organ or tissue transplant rejection
US6693173B2 (en) 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
CN1330668C (en) 2001-01-05 2007-08-08 辉瑞大药厂 Antibodies to insulin-like growth factor I receptor
ES2184594B1 (en) 2001-01-17 2004-01-01 Probitas Pharma Sa PROCEDURE FOR THE PRODUCTION OF GAMMAGLOBULINA G HUMANA INACTIVADA OF VIRUS.
CZ20032208A3 (en) 2001-02-23 2004-01-14 Immunex Corporation Increased yield of active proteins
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP1405331A1 (en) 2001-06-25 2004-04-07 Koninklijke Philips Electronics N.V. High-pressure gas discharge lamp and method of manufacturing the same
TR201809678T4 (en) 2001-06-26 2018-07-23 Amgen Fremont Inc Antibodies against opgl.
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
DK1425389T3 (en) * 2001-08-23 2012-01-30 Genmab As Interleukin-15- (IL-15) -specific human antibodies
JP2005527474A (en) 2001-09-20 2005-09-15 コーネル リサーチ ファンデーション インコーポレーテッド Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
WO2003039485A2 (en) 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US20030143603A1 (en) 2001-11-30 2003-07-31 Jill Giles-Komar Anti-TNF antibodies, compositions, methods and uses
MXPA04006053A (en) 2001-12-21 2005-03-31 Immunex Corp Methods for purifying protein.
KR20040085185A (en) 2002-02-14 2004-10-07 추가이 세이야쿠 가부시키가이샤 Antibody-containing solution pharmaceuticals
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
SI1946776T1 (en) 2002-02-27 2017-07-31 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
EP1497444B1 (en) 2002-03-27 2015-11-04 Immunex Corporation Methods for increasing polypeptide production
MXPA04009681A (en) 2002-04-05 2005-01-11 Amgen Inc Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors.
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AU2003251592A1 (en) 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
CN102755646A (en) 2002-07-19 2012-10-31 艾博特生物技术有限公司 Medicament for treating TNF alpha related disorder
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DE60326012D1 (en) 2002-11-01 2009-03-12 Bayer Healthcare Llc Method for concentration of proteins
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
CN101287484B (en) 2002-12-20 2012-10-10 安姆根有限公司 Binding agents which inhibit myostatin
CA2518980A1 (en) 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
EP3178492A1 (en) 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
DK1624864T3 (en) 2003-05-14 2015-02-23 Danisco Us Inc Controlled release of active agents by the use of the repeat sequence protein polymers
EP1631317A2 (en) 2003-06-06 2006-03-08 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
PL1639011T3 (en) 2003-06-30 2009-05-29 Domantis Ltd Pegylated single domain antibodies (dAb)
CN1886426A (en) 2003-11-07 2006-12-27 伊姆尼斯公司 Antibodies that bind interleukin-4 receptor
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
RU2390353C2 (en) 2004-02-12 2010-05-27 Мерк Патент Гмбх High-concentration liquid anti-egfr antibody compositions
WO2005095454A1 (en) 2004-03-25 2005-10-13 Diadexus, Inc. Lng105 antibody composition and methods of use, and use of lng105 to assess lung cancer risk
US8333995B2 (en) 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
JPWO2006003999A1 (en) 2004-07-05 2008-07-31 財団法人化学及血清療法研究所 Human anti-human B7RP-1 antibody and antibody fragment thereof
WO2006012965A1 (en) * 2004-07-29 2006-02-09 Merck Patent Gmbh Difluorosubstituted heterocyclic compounds and the use thereof in the form of components in liquid crystalline media
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
KR20070072510A (en) 2004-08-30 2007-07-04 론자 바이올로직스 피엘씨 Affinity-plus ion exchange-chromatography for purifying antibodies
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
WO2006064373A2 (en) 2004-12-16 2006-06-22 Genzyme Polyclonals S.A.S. Methods of purifying immunologlobulins
JP4498939B2 (en) 2005-02-01 2010-07-07 東京応化工業株式会社 Positive resist composition and resist pattern forming method
US8597709B2 (en) 2005-04-12 2013-12-03 Inovobiologic Inc. Dietary supplement and methods of use
AU2006259664A1 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070049732A1 (en) 2005-09-01 2007-03-01 Zurlo Eugene J Ultra-high yield intravenous immune globulin preparation
ZA200803448B (en) 2005-09-21 2009-10-28 Burcon Nutrascience Mb Corp Preparation of canola protein isolate involving isoelectric precipitation
US8067350B2 (en) 2005-12-15 2011-11-29 Kimberly-Clark Worldwide, Inc. Color changing cleansing composition
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
MX2008013535A (en) 2006-04-21 2008-10-29 Amgen Inc Buffering agents for biopharmaceutical formulations.
KR101317235B1 (en) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 Antagonist anti-cd40 antibody pharmaceutical compositions
WO2008033556A2 (en) 2006-09-15 2008-03-20 Barofold, Inc. High pressure treatment of proteins for reduced immunogenicity
WO2008057240A2 (en) 2006-10-27 2008-05-15 Abbott Biotechnology Ltd. Crystalline anti-htnfalpha antibodies
US20080213282A1 (en) 2006-12-21 2008-09-04 Jaby Jacob Formulations
TWI543768B (en) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20100138908A (en) * 2008-02-07 2010-12-31 암젠 인코퍼레이티드 Stabilized protein compositions
US8052645B2 (en) 2008-07-23 2011-11-08 Avant Medical Corp. System and method for an injection using a syringe needle
JP5836120B2 (en) 2008-05-20 2015-12-24 アヴァント・メディカル・コーポレーション Auto injector system
US8177749B2 (en) 2008-05-20 2012-05-15 Avant Medical Corp. Cassette for a hidden injection needle
EP2331090B1 (en) * 2008-09-19 2018-01-03 Pfizer Inc. Stable liquid antibody formulation
RU2481824C2 (en) * 2008-10-29 2013-05-20 Аблинкс Н.В Preparations of single domain antigen-binding molecules
BRPI1006519A2 (en) 2009-03-06 2016-08-09 Genentech Inc antibody formulation
US20110070227A1 (en) 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
NZ609469A (en) 2010-11-11 2015-02-27 Abbvie Biotechnology Ltd Improved high concentration anti-tnfα antibody liquid formulations
US9084849B2 (en) * 2011-01-26 2015-07-21 Kaleo, Inc. Medicament delivery devices for administration of a medicament within a prefilled syringe
WO2012143418A1 (en) * 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
DK2699293T3 (en) 2011-04-20 2019-04-29 Amgen Inc AUTO INJECTION DEVICE
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
BR112013033671B1 (en) 2011-07-01 2022-10-18 Biogen Ma Inc ARGININE-FREE FC FUSION POLYPEPTIDE COMPOSITIONS AND USE
KR20140079491A (en) * 2011-10-18 2014-06-26 코히러스 바이오사이언시즈, 인코포레이티드 Etanercept formulations stabilized with combinations of sugars and polyols
US20150150982A1 (en) * 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
AU2013286669B2 (en) 2012-07-05 2018-02-01 Unl Holdings Llc Automatic injectors for injectable cartridges and drive control mechanisms therefor
MX2015000337A (en) * 2012-07-09 2015-09-25 Coherus Biosciences Inc Etanercept formulations exhibiting marked reduction in sub-visible particles.
PE20150996A1 (en) * 2012-09-11 2015-08-01 Coherus Biosciences Inc PROPERLY FOLDED ETANERCEPT FOR HIGH PURITY AND EXCELLENT PERFORMANCE
RU2664691C2 (en) * 2012-10-26 2018-08-21 Люпин Лимитед Stable pharmaceutical composition of tnfr: fc fusion protein
US9649383B2 (en) 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
KR101419884B1 (en) * 2012-11-27 2014-07-16 (주)알테오젠 Formulation composition for stabilizing fusion proteins with IgG Fc domain
WO2014106116A2 (en) 2012-12-28 2014-07-03 Abbott Cardiovascular Systems Inc. Delivery of biologic therapeutics
EP2968775B1 (en) 2013-03-15 2019-12-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
ES2973257T3 (en) 2013-03-15 2024-06-19 Amgen Inc Drug cassette, autoinjector and autoinjector system
MX2015015051A (en) * 2013-05-02 2016-06-10 Mabxience S A Alternative formulations for tnfr: fc fusion polypeptides.
CN105611938A (en) * 2013-10-24 2016-05-25 免疫医疗有限责任公司 Stable, aqueous antibody formulations
US9700595B2 (en) 2013-11-29 2017-07-11 Ares Trading Sa Liquid formulation of a fusion protein comprising TNFR and Fc region
ES2733298T3 (en) 2014-07-18 2019-11-28 Sandoz Ag Quantification of TNFR2: Fc erroneously folded
US10799649B2 (en) 2014-08-28 2020-10-13 Unl Holdings Llc Sensor systems for drug delivery devices
CA2959159C (en) 2014-08-28 2023-05-23 Unitract Syringe Pty Ltd Skin sensors for drug delivery devices
CN107205925B (en) * 2014-12-22 2020-12-11 阿雷斯贸易股份有限公司 Liquid pharmaceutical composition
KR20170138426A (en) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 Anti-TNF-alpha polypeptide compositions and uses thereof
US9763976B1 (en) 2016-08-02 2017-09-19 Zo Skin Health, Inc. Composition and method for treating skin conditions
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same

Also Published As

Publication number Publication date
JP6884858B2 (en) 2021-06-09
AU2017345490A1 (en) 2019-05-09
WO2018075818A1 (en) 2018-04-26
JP2021120393A (en) 2021-08-19
US11491223B2 (en) 2022-11-08
JP7402195B2 (en) 2023-12-20
CN114917185B (en) 2023-11-14
US20190022217A1 (en) 2019-01-24
MX2019004580A (en) 2019-08-12
US20180110856A1 (en) 2018-04-26
KR20210158878A (en) 2021-12-31
US20230080571A1 (en) 2023-03-16
CN114917185A (en) 2022-08-19
BR112019007858A2 (en) 2019-07-02
CN109982685B (en) 2022-03-11
US10307483B2 (en) 2019-06-04
JP2019533679A (en) 2019-11-21
IL266132B (en) 2021-12-01
US20180256718A1 (en) 2018-09-13
EP3528787A4 (en) 2020-05-06
CN109982685A (en) 2019-07-05
KR20190071760A (en) 2019-06-24
KR102413592B1 (en) 2022-06-27
EA201990998A1 (en) 2019-11-29
JP2024010026A (en) 2024-01-23
KR102446838B1 (en) 2022-09-26
CL2019001053A1 (en) 2019-08-02
EP3528787A1 (en) 2019-08-28
AU2017345490B2 (en) 2022-07-07
IL266132A (en) 2019-06-30
CA3040899A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
SG11201903521XA (en) Pharmaceutical formulations and methods of making the same
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201907023UA (en) Method of reducing neutropenia
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201807912SA (en) Vaccine against rsv
SG11201811549UA (en) Boronic acid derivatives and therapeutic uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201408054RA (en) Pegylated oxm variants
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases